<![CDATA[Salt-Formulation Cabozantinib Capsules Receive FDA Tentative Approval in RCC, HCC, epNET]]>

RegulatoryapprovedCabozantinibPositive

AI Analysis

Summary

Exelixis's cabozantinib alternate-salt capsule formulation received FDA tentative approval for advanced renal cell carcinoma, hepatocellular carcinoma, and neuroendocrine tumors. This represents a regulatory milestone for the company's existing oncology portfolio.

Outcome Details

FDA tentative approval for salt-formulation cabozantinib capsules

Importance:6/10

Sentiment:

0.85

FDA approvalcabozantinibRCCHCCneuroendocrine tumorsformulation

Related Companies

$EXEL

Read the original article

Published by Cancer Network on August 3, 2026 3:26 PM

Read Original